Key facts
- It has raised $86.6M across 7 recorded rounds; the latest was Later Stage VC (Series B) ($35.2M) in Oct 2023.
- DermBiont has filed 12 Form Ds with the SEC since 2019, most recently Nov 2024 ($32.7M sold to 72 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 7 rounds
- ·Watchlist + deal alerts for DermBiont
Create free account
No card required
Funding rounds
7 roundsOct 2023Later Stage VC (Series B)$35.2M▮
Dec 2021Early Stage VC (Series A2)$35.4M▮
Oct 2020Early Stage VC (Series A2)$7.2M▮
About DermBiont
- Industry
- Drug Discovery
PA Mark — not yet priced
DermBiont doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in DermBiont shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on DermBiont in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.